Division of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Vienna, Austria Austrian Society of Applied Pharmacokinetics, Vienna, Austria
Department of Oncology, University Clinic of Internal Medicine I, Medical University Vienna, General Hospital Vienna, Vienna, Austria Austrian Society of Applied Pharmacokinetics, Vienna, Austria.
Anticancer Res. 2014 Jul;34(7):3669-73.
Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer. This study was designed to investigate whether co-administration of the monoclonal antibody bevacizumab (BVZ) shows potential to modulate the plasma disposition of capecitabine (CCB) and its metabolites.
Nine patients treated with CCB and BVZ for advanced colorectal cancer entered this pharmacokinetic study. In the first cycle CCB was given alone at doses of 1,250 mg/m2 bi-daily for two weeks with one week rest. In the second cycle BVZ co-administration started simultaneously with oral intake of CCB by short infusion of 7.5 mg/kg.
Mean plasma concentration time curves of CCB and its metabolites were insignificantly lower in the BVZ combination regimen compared to CCB monotherapy. After repeated cycles of BVZ no significant pharmacokinetic interaction was observed.
From the pharmacokinetic point of view and in agreement with numerous clinical study data, co-administration of BVZ with CCB appears to be safe and efficient.
卡培他滨是一种细胞毒性药物 5-氟尿嘧啶的前体药物，广泛用于结直肠癌的治疗。本研究旨在探讨贝伐单抗（BVZ）联合给药是否有可能调节卡培他滨（CCB）及其代谢物的血浆处置。
9 例接受卡培他滨和贝伐单抗联合治疗的晚期结直肠癌患者入组本药代动力学研究。在第一个周期中，卡培他滨单独使用，剂量为 1250mg/m2，每日两次，连用两周，休息一周。在第二个周期中，贝伐单抗与卡培他滨同时口服，短时间输注 7.5mg/kg。
与卡培他滨单药治疗相比，贝伐单抗联合治疗方案中卡培他滨及其代谢物的平均血浆浓度时间曲线无显著降低。经过多次贝伐单抗重复周期，未观察到明显的药代动力学相互作用。
从药代动力学角度来看，并与大量临床研究数据一致，贝伐单抗与卡培他滨联合给药似乎是安全有效的。
